Zosano Pharma to showcase new post-hoc analyses of Qtrypta’s (M207) clinical trial data comparing key efficacy results from the pivotal study and the open-label long term safety study on the 2020 American Headache Society’s Virtual Annual Scientific Meeting Platform
13 juin 2020 06h00 HE
|
Zosano Pharma Corporation
FREMONT, Calif., June 13, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that new post-hoc efficacy analyses of...
Zosano Pharma Announces Change to a Virtual Meeting Format for 2020 Annual Meeting of Stockholders
11 juin 2020 16h05 HE
|
Zosano Pharma Corporation
FREMONT, Calif., June 11, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN) (the “Company” or “Zosano”), a clinical-stage biopharmaceutical company, today announced a change in the...
Zosano Pharma Reports First Quarter 2020 Financial Results and Provides Corporate Update
14 mai 2020 17h05 HE
|
Zosano Pharma Corporation
FREMONT, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended...
Zosano Pharma Announces the Appointment of Christine Matthews as Chief Financial Officer
01 mai 2020 16h35 HE
|
Zosano Pharma Corporation
FREMONT, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Christine Matthews as the...
Zosano Pharma Reports Fourth Quarter and Fiscal Year 2019 Financial Results
13 mars 2020 08h00 HE
|
Zosano Pharma Corporation
FREMONT, Calif., March 13, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and...
Zosano Pharma Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market
06 mars 2020 17h15 HE
|
Zosano Pharma Corporation
FREMONT, Calif., March 06, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN) (“Zosano”), a clinical-stage biopharmaceutical company, today announced that it has closed its...
Zosano Pharma Announces $11 Million Registered Direct Offering Priced At-the-Market
05 mars 2020 08h00 HE
|
Zosano Pharma Corporation
FREMONT, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN) (“Zosano”), a clinical-stage biopharmaceutical company, today announced that it has entered into...
Zosano Pharma Announces FDA Acceptance of 505(b)(2) New Drug Application for Qtrypta™ for the Acute Treatment of Migraine
04 mars 2020 08h00 HE
|
Zosano Pharma Corporation
FREMONT, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq: ZSAN), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...
Zosano Pharma Announces Pricing of $8.0 Million Public Offering of Common Stock and Warrants
12 févr. 2020 08h20 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN) (the “Company” or “Zosano”), a clinical-stage biopharmaceutical company, today announced the pricing of...
Zosano Pharma Announces Proposed Public Offering of Common Stock and Warrants
11 févr. 2020 16h35 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it is commencing an underwritten public...